QuestCor QSC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QuestCor QSC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter R Smith who wrote (71)	2/11/1998 9:54:00 PM
From: gcrispin	Read Replies (2) of 120

Just returned from the annual shareholder meeting. Cypros is planning for a busy and productive year. They are searching for a manufacturer for their DIMAC system that they recently acquired. Expect to get that off the ground in six to nine months. They have a meeting with the FDA in late March to discuss their phase III trial for sickle cell crisis. They expect to start their trial immediately. The trial will include 200 to 300 patients. They are also planing to begin a phase III trial for closed head injury with their drug Ceresine. They expect to proceed with approximately 200 patients, then review data before proceeding with a large 900 patient trial. The February issue of NeuroInvestment had a four page review of CYPR, updating what is going on with the company. I sensed an atmosphere of anticipation and excitement among the staff. The management is truly geared to making this company work. As I have stated earlier, Harvard University is the largest stockholder. Dr. Paul Marangos, founder of the company is second. In my opinion the rewards are greater than the risks, especially at these prices. Can you give me further information about this analyst from Cohen?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next